Global Engineered TCR and CAR Immunotherapeutics Analysis Report 2015

News provided by

Mar 20, 2015, 09:19 ET

DUBLIN, Mar. 19, 2015 /PRNewswire/ --Research and Markets

(http://www.researchandmarkets.com/research/brpjgz/engineered_tcr) has announced the addition of the "Engineered TCR and CAR Immunotherapeutics 2015" report to their offering.

This report Engineered TCR and CAR Immunotherapeutics 2015: A comparative analysis of the landscape of and business opportunities with TCR and CAR antibodies, T cells, NK cells, TILs, DLIs & DLIs as of March 2015 brings you up-to-date regarding key players, key technologies, TCR and CAR immunotherapeutic projects, business deals and private and public financing rounds.

The report analyzes the TCR and CAR immunotherapeutic pipelines and stakeholders in the field, especially among Big Pharma/Biotech and technology companies. The report highlights the value of TCR and CAR immunotherapeutics in terms of partnering economic conditions, private financing rounds and (initial) public offerings with the resulting market capitalization of companies.

However, progress in clinical trials and supply of clinical grade batches reveals some major limitations which need to be surmounted and the problems solved if TCR and CAR immunotherapeutics want to become commercially viable and successful products. This report describes the challenges and limitations and identifies solutions provided by new technologies which offer tremendous business opportunities.

This report has been built in a bottom-up basis by desktop search to identify and describe company, product, technology and business/financing profiles which then are evaluated and analyzed with a final outlook describing perspectives with challenges and opportunities.

What will you find in the report?

Profiles of TCR and CAR immunotherapeutics in development
Competitor analysis of CD19 CAR T cells
Options to improve CAR T cells regarding efficacy, safety, manufacturing and commercial value
Target analysis of TCR T cells in R&D
CAR T Cell pipeline in hematology
CAR T Cell pipeline in solid tumors
Allogeneic TCR and CAR T cells in R&D
Universal antibody-targeted CAR T cells and NK cells
Pipeline of most promising TILs, NK cells, DLIs and CTLs
Technologies needed for next generations of TCR and CAR immunotherapeutics
Profiles of biotechnology companies incl. financing and licensing/partnering
Profiles and scope of interest of Big Pharma/Biotech companies for TCRs & CARs
Stakeholder analysis (established, emerging, non-US, technology providing companies)
Potential of alternative adoptive immunotherapies with NK cells, TILs, CTLs and DLIs
Analysis of major partnering deals between Big pharma and technology companies
Economic terms of pharma-biotech deals
Opportunities for biotech-biotech deals in the TCR and CAR field
Potential to raise private money with TCR and CAR technologies
Success in initial public offerings and follow on offerings with TCRs and CARs
Limitations and hurdles with current TCR and CAR immunotherapeutics
Opportunities for novel TCR and CAR immunotherapeutics
Pricing of TCR and CAR immunotherapeutics
Aspects of manufacturing and commercialization

Who will benefit from the report?

Venture capital, private equity and investment managers
Financial analysts
CFO
Business development and licensing (BDL) specialists
Marketing managers
CEO, COO and managing directors
Corporate strategy, product and portfolio analysts and managers
Chief Technology Officer
Cell technology and manufacturing specialists
Clinical and preclinical development specialists

Key Topics Covered:

1 Introduction

2 Executive Summary

3 Profiles of TCR & CAR Immunotherapeutics, NK Cells, TILs, DLIs and CTLs

4 Pipeline Analysis

5 Technology Companies

6 Pharmaceutical Companies

7 Stakeholder Analysis

8 Selected Technology Profiles

9 Business Perspective on TCR and CAR Immunotherapeutics

10 Outlook for TCR and CAR Immunotherapeutics

Companies Mentioned